Skip to main content
. Author manuscript; available in PMC: 2016 Jun 28.
Published in final edited form as: J Control Release. 2015 Feb 3;208:59–66. doi: 10.1016/j.jconrel.2015.02.001

Fig. 5. In vivo antitumor efficacy of (Dox + 17-AAG)/NG in ErbB2+ - BT-474 breast cancer mice model.

Fig. 5

Relative changes in (A) tumor volume and (B) body weight were measured following intravenous administration of (Dox + 17-AAG)/NG (▲) or Dox/NG (●) or Dox + 17-AAG (♦) or Free Dox (Ø) or 17-AAG/NG (■) or 5% dextrose (▼). Drug formulations were injected in 100 µL at a dose of 6 mg Dox or 1mg 17-AAG equivalents/kg body weight 4 times at 4-day intervals as indicated by the arrows. Values indicated are means ± SEM (n = 10). (C) Kaplan–Meier analysis of overall survival in (Dox + 17-AAG)/NG group (1) or Dox/NG group (2) or Dox + 17-AAG group (3) or Dox alone (4) or 17-AAG/NG group (5) or control group (6). Tumor volume and body weight are normalized with respect to tumor volume or body weight at day 0. * P<0.05, ** P<0.01.